Anthracycline compounds are major culprits in chemotherapy-induced cardiotoxicity, which is the chief limiting factor in delivering optimal chemotherapy to cancer patients. Although extensive efforts have been devoted to identifying strategies to prevent anthracycline-induced cardiotoxicity, there is little consensus regarding the best approach. Recent advances in basic mechanisms of anthracycline-induced cardiotoxicity provided a unified theory to explain the old reactive-oxygen species hypothesis and identified topoisomerase 2b as the primary molecular target for cardioprotection. This review outlines current strategies for primary and secondary prevention of anthracycline-induced cardiotoxicity resulting from newly recognized molecular mechanisms and identifies knowledge gaps requiring further investigation. (J Am Coll Cardiol 2014;64:938-45)
T he U.S. National Cancer Institute estimates that at least 13.7 million cancer survivors were alive in the United States in 2012 and that this number will approach 18 million by 2022 (1) . A total of 67% of adults diagnosed with cancer today will be alive in 5 years, and 75% of children diagnosed with cancer today will be alive in 10 years.
Cancer chemotherapy or radiotherapy can cause short-and long-term cardiovascular complications.
In a U.S. National Health and Nutrition Examination survey of 1,807 cancer survivors followed for 7 years, 33% died of heart diseases and 51% of cancer (2) .
The primary cause of chemotherapy-induced cardiotoxicity is anthracycline compounds, which are used extensively to treat lymphoma, sarcoma, breast cancer, and pediatric leukemia ( Table 1) .
Despite efforts to identify risk factors, develop less-toxic derivatives, and detect subclinical toxicity earlier, there is no consensus on the best approach to prevent anthracycline-induced cardiotoxicity.
Recent advances in the molecular basis of anthracycline-induced cardiotoxicity might lead to better cardioprotective strategies.
RISK FACTORS FOR ANTHRACYCLINE-INDUCED CARDIOTOXICITY
Cardiac complications were first reported a few years after the introduction of daunorubicin (3) . In 1979, a dose-toxicity curve was generated by plotting the incidence of heart failure (defined by clinical signs and symptoms such as shortness of breath, neck vein distension, S3 gallop, cardiomegaly, hepatomegaly, or pericardial effusion) against the total anthracycline dose used in many studies (4) . Heart failure incidences were 3%, 7%, and 18% in patients who had received a cumulative dose of 400, 550, or 700 mg/m 2 of doxorubicin, respectively. Therefore, oncologists usually limited the cumulative anthracycline dose to #550 mg/m 2 (5) . The introduction of cardiac imaging technology that allows detection of heart failure or even asymptomatic left ventricular (LV) dysfunction led to the realization that incidence of anthracycline-induced cardiotoxicity was higher than previously estimated. In 2003, heart failure incidences of 5%, 16%, and 26% were estimated for cumulative doxorubicin doses of 400, 500, and 550 mg/m 2 , respectively (6) , resulting in a modification to limit the cumulative anthracycline dose to 400
to 450 mg/m 2 .
Cardiac biopsy has been used to evaluate cardiac damage in patients who received anthracycline treatment, with morphological changes graded by the Billingham system (7). This system assesses the severity of cardiotoxicity using the degree of myofi- Anthracycline-induced cardiomyopathy has been classified as early or late onset using a cutoff of 1 year after anthracycline treatment (10) . Cumulative incidences of cardiac events peaked at 1 year after anthracycline treatment (11, 12) . The actual incidence of late cardiotoxicity is difficult to ascertain because of a lack of good studies. The multicenter Childhood
Cancer Survivor Study reported that additional cancer treatment or other cardiovascular risk factors might play an important role in causing late-onset cardiomyopathy (13) . This study also reported that cardiovascular risk factors, such as hypertension, diabetes, dyslipidemia, and obesity, are significantly higher in cancer survivors than in the healthy population (13) .
MECHANISMS OF ANTHRACYCLINE-INDUCED CARDIOTOXICITY
Previously, the most widely accepted hypothesis for anthracycline-induced cardiomyopathy was the generation of excess reactive oxygen species (ROS) by electron exchange between the anthracycline quinone moiety and oxygen molecules and other cellular electron donors (14) . Anthracyclines also form complexes with iron that undergo redox cycling and generate oxygen radicals (15 In the inset, dexrazoxane was shown to bind to Top2b to prevent anthracycline binding.
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Prevention of Anthracycline Cardiotoxicity (43, 44) . However, concurrently administered dexrazoxane might interfere with anthracycline's antitumor efficacy (44) . In the 088001 trial, the dexrazoxane arm had a lower response rate; however, times to progression and survival rates were not significantly different (44) . Of note, this study was not replicated by other clinical trials (44) Consistent with another retrospective study identifying female sex as an independent risk factor for anthracycline-induced cardiotoxicity (47), reduced LV fractional shortening was greater in girls than in boys in the doxorubicin-only group across a 5-year period (38) . Moreover, dexrazoxane provides greater cardioprotection for girls than for boys (38) . Five years after treatment, girls who received doxorubicin with dexrazoxane had better fractional shortening and a better end-diastolic thickness-to-dimension ratio than those who received doxorubicin alone (38) .
Animal studies suggest that hormonal status or body fat percentage might cause the higher incidence of cardiotoxicity found in girls (48) . Although the reason for its potency in girls is unknown, dexrazoxane clearly provides long-term cardioprotection without compromising anthracycline's antitumor efficacy.
With a median 8.7-year follow-up interval, event-free survival rates were similar in patients who received concurrent dexrazoxane and in those who received doxorubicin alone (76% vs. 77%, p ¼ 0.99) (38) .
Another controversy is the potential risk of increased secondary malignancy, which was reported in 1 study that added dexrazoxane to the standard pediatric Hodgkin lymphoma regimen (49) . Two other studies of childhood ALL reported no differences in secondary malignancy incidence between dexrazoxane and placebo groups at 5-or 10-year follow-up (50, 51) . Taken together, dexrazoxane is unlikely to increase secondary malignancy risk.
BETA-BLOCKERS, ACE INHIBITORS, OR ARBS.
Betablockers, ACE inhibitors, and ARBs were evaluated in randomized controlled trials for primary prevention of anthracycline-induced cardiotoxicity ( Table 3) .
LVEF dropped significantly after chemotherapy in placebo or control groups, but not in intervention *Numbers in parentheses represent the numbers of patients in intervention and control/placebo groups, respectively. †Statistically significant between baseline and 6 months (p < 0.05). ‡Medications titrated as tolerated. §Medications started on the first day of chemotherapy and continued throughout the study. kMedications started within 1 week before the first chemotherapy cycle and continued for 6 months.
ACE ¼ angiotensin-converting enzyme; LVEF ¼ left ventricular ejection fraction; TnI ¼ troponin I.
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groups. Despite these declines, LVEFs remained >50% (52-54). The major limitation of these studies is the short-term (5 to 6 months) follow-up. Whether beneficial hemodynamic effects or primary protection were responsible for these results is unclear. Over a median 31-month follow-up period (the longest of 4 studies), no differences in echocardiographic parameters or heart failure incidence were observed during doxorubicin treatment in lymphoma patients randomized to receive metoprolol, enalapril, or nothing (55) . Another trial monitored TnI, the best cardiac injury marker, during anthracycline therapy.
TnI leakage did not differ significantly between the control and intervention groups (4 patients vs. Table 2 .
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Prevention of Anthracycline Cardiotoxicity dexrazoxane, liposomal doxorubicin, or continuous infusion ( Table 4) .
Clinicians should be alerted to early signs of anthracycline-induced cardiotoxicity by a combination of biomarker and imaging studies. Guidelines developed through expert consensus recommend the frequency and modality of testing for secondary prevention (59) . Standard heart failure treatment should generally be initiated with the earliest detection of cardiotoxicity (66) ( Prevention of Anthracycline Cardiotoxicity S E P T E M B E R 2 , 2 0 1 4 : 9 3 8 -4 5
